202 related articles for article (PubMed ID: 21686163)
1. 3D-QSAR studies on a series of dihydroorotate dehydrogenase inhibitors: analogues of the active metabolite of leflunomide.
Li SL; He MY; Du HG
Int J Mol Sci; 2011; 12(5):2982-93. PubMed ID: 21686163
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
Kim TH; Na HS; Löffler M
Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
[TBL] [Abstract][Full Text] [Related]
3. 1,2,5-Oxadiazole analogues of leflunomide and related compounds.
Giorgis M; Lolli ML; Rolando B; Rao A; Tosco P; Chaurasia S; Marabello D; Fruttero R; Gasco A
Eur J Med Chem; 2011 Jan; 46(1):383-92. PubMed ID: 21109332
[TBL] [Abstract][Full Text] [Related]
4. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Leban J; Vitt D
Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
[TBL] [Abstract][Full Text] [Related]
5. Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
Chibli LA; Schmidt TJ; Nonato MC; Calil FA; Da Costa FB
Eur J Med Chem; 2018 Sep; 157():852-866. PubMed ID: 30145372
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
8. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Liu S; Neidhardt EA; Grossman TH; Ocain T; Clardy J
Structure; 2000 Jan; 8(1):25-33. PubMed ID: 10673429
[TBL] [Abstract][Full Text] [Related]
9. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
10. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
11. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
12. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
13. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
Heidarian R; Zahedi-Tabrizi M
Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Kuo EA; Hambleton PT; Kay DP; Evans PL; Matharu SS; Little E; McDowall N; Jones CB; Hedgecock CJ; Yea CM; Chan AW; Hairsine PW; Ager IR; Tully WR; Williamson RA; Westwood R
J Med Chem; 1996 Nov; 39(23):4608-21. PubMed ID: 8917650
[TBL] [Abstract][Full Text] [Related]
15. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors.
Bonomo S; Tosco P; Giorgis M; Lolli M; Fruttero R
J Mol Model; 2013 Mar; 19(3):1099-107. PubMed ID: 23143678
[TBL] [Abstract][Full Text] [Related]
16. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
17. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
19. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive agent leflunomide: a SWNTs-immobilized dihydroortate dehydrogenase inhibitory effect and computational study of its adsorption properties on zigzag single walled (6,0) carbon and boron nitride nanotubes as controlled drug delivery devices.
Raissi H; Mollania F
Eur J Pharm Sci; 2014 Jun; 56():37-54. PubMed ID: 24566615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
